During the last month, we have seen a substantial increase in the amount of interest in the psychedelic market and this is an opportunity that we are closely following. We have been focused on identifying potential leaders in the psychedelic market and want to highlight a business that caught our attention.
WAKE Network is an emerging opportunity that is focused on advancing fungi and plant-based medicine by leveraging clinical research, wellness professionals, and technology. The company has developed a regenerative feedback loop that allows it to research, monitor and incorporate results from clinical studies to personalize medicine to reduce the level of ambiguous results from traditional medicine.
One of the reasons we are excited about WAKE is related to the structure of the business. The company operates an integrated business model that provides it with multiple revenue streams and we are bullish on the amount of synergies that can found between the following divisions:
- Clinics: Has a clinical immersion platforms in Jamaica, the Netherlands, California, the British Virgin Islands, and Brazil.
- Research: Formed strategic partnerships that are focused on R&D and technology
- Products: Develops and sells functional mushroom supplements through a direct-to-consumer model. The company plans to expand to plant medicine and psilocybin derived treatments
- Intellectual Property (IP): The company is working on being granted patents for proprietary formulations, strains, dosing, therapy protocols, and delivery methods
Earlier this year, Wake Clinics opened a 3,000-acre mountain retreat, private beach and pavilion in Jamaica. The facility offers psilocybin-based therapy where licensed professionals assess patients and track biofeedback. Therapists who work at the clinic provide ongoing monitoring to ensure the full integration of the healing process.
One of the ways WAKE Network has been able to differentiate itself is through the work it has accomplished in Jamaica. Wake Jamaica is a separate division of the business and is a cultivation-focused joint venture subsidiary that is managed by Pauline Smith and her group of mycologists and farmers. We are bullish on the growth prospects that are associated with the division and will monitor how this aspect of the story advances from here.
The other division of WAKE is focused on the development of a line of premium functional mushroom products. During the last decade, we have seen a substantial increase in the level of demand for functional mushrooms and are bullish on the trend. All of the functional mushrooms that produced by WAKE are organic and we are favorable on this aspect of the story.
From a management team standpoint, WAKE Network is led by a team that has diverse expertise in a variety of industries and we find this to be significant. Dr. Olga Chernoloz is one of the most important members of the team and is the director of the psychedelic research at Wake Network.
We are favorable on the experience that Dr. Chernoloz brings to the business. Dr Chernoloz serves as a scientific advisor to The Toronto Centre for Psychedelic Science and has extensive experience providing scientific advisory services to cannabis and psychedelic companies. Dr Chernoz will play a key role in the success of the business.
WAKE Network represents a differentiated opportunity with significant potential catalysts. Over the next year, we expect the company to record notable advancements related to the assets in Jamaica and with its clinics. This is an opportunity that we will be putting on our radar and will provide updates as needed.
If you are interested in learning WAKE Network, please send an email to firstname.lastname@example.org to be added to our distribution list.